The functional impact of variants of uncertain significance in BRCA2

[1]  Chunling Hu,et al.  Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. , 2018, American journal of human genetics.

[2]  S. Cross,et al.  BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. , 2017, Cancer research.

[3]  Yuyang Jiang,et al.  PARP inhibitors as antitumor agents: a patent update (2013-2015) , 2017, Expert opinion on therapeutic patents.

[4]  A. Celetti,et al.  Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic , 2016, Journal of Experimental & Clinical Cancer Research.

[5]  Alexandre Orthwein,et al.  BRCA2 functions: from DNA repair to replication fork stabilization. , 2016, Endocrine-related cancer.

[6]  A. Nicolas,et al.  Functional Assessment of Genetic Variants with Outcomes Adapted to Clinical Decision-Making , 2016, PLoS genetics.

[7]  Fergus J Couch,et al.  Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance , 2016, npj Genomic Medicine.

[8]  Alan Ashworth,et al.  BRCAness revisited , 2016, Nature Reviews Cancer.

[9]  J. Garber,et al.  PARP inhibitors in the management of breast cancer: current data and future prospects , 2015, BMC Medicine.

[10]  F. Couch,et al.  BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Florent Baty,et al.  Dose-Response Analysis Using R , 2015, PloS one.

[12]  G. Hendriks,et al.  An Efficient Pipeline for the Generation and Functional Analysis of Human BRCA2 Variants of Uncertain Significance , 2014, Human mutation.

[13]  D. Pruss,et al.  A comprehensive laboratory‐based program for classification of variants of uncertain significance in hereditary cancer genes , 2014, Clinical genetics.

[14]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[15]  F. Couch,et al.  Functional Assays for Analysis of Variants of Uncertain Significance in BRCA2 , 2014, Human mutation.

[16]  Peter Bouwman,et al.  A high-throughput functional complementation assay for classification of BRCA1 missense variants. , 2013, Cancer discovery.

[17]  Diana Eccles,et al.  Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. , 2013, Journal of the National Cancer Institute.

[18]  F. Couch,et al.  BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management. , 2013, The oncologist.

[19]  T. Ludwig,et al.  Double-strand break repair by homologous recombination in primary mouse somatic cells requires BRCA1 but not the ATM kinase , 2013, Proceedings of the National Academy of Sciences.

[20]  Adam P. Rosebrock,et al.  A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. , 2013, Molecular cell.

[21]  Paolo Radice,et al.  A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity. , 2013, Cancer research.

[22]  D. Pruss,et al.  Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay. , 2012, Human molecular genetics.

[23]  Sue Healey,et al.  ENIGMA—Evidence‐based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes , 2012, Human mutation.

[24]  Fergus J Couch,et al.  A review of a multifactorial probability‐based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS) , 2012, Human mutation.

[25]  Fergus J Couch,et al.  A Computational Method to Classify Variants of Uncertain Significance Using Functional Assay Data with Application to BRCA1 , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[26]  S. Powell,et al.  BRCA1 and BRCA2: different roles in a common pathway of genome protection , 2011, Nature Reviews Cancer.

[27]  A. Spurdle,et al.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.

[28]  S. Sharan,et al.  Mouse embryonic stem cell–based functional assay to evaluate mutations in BRCA2 , 2008, Nature Medicine.

[29]  H A Risch,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions , 2008, British Journal of Cancer.

[30]  A. Ashworth,et al.  The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability , 2006, Oncogene.

[31]  F. Couch,et al.  Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. , 2006, Molecular cell.

[32]  J. C. Houwelingen,et al.  Cancer risks in BRCA2 families: estimates for sites other than breast and ovary , 2005, Journal of Medical Genetics.

[33]  Marco Foiani,et al.  DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1 , 2004, Nature.

[34]  T. Mak,et al.  Developmental Studies of Brca1 and Brca2 Knock-Out Mice , 1998, Journal of Mammary Gland Biology and Neoplasia.

[35]  Ashok R Venkitaraman,et al.  Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.

[36]  M. Jasin,et al.  BRCA2 is required for homology-directed repair of chromosomal breaks. , 2001, Molecular cell.

[37]  D E Goldgar,et al.  Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. , 1997, American journal of human genetics.

[38]  G. Eichele,et al.  Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 , 1997, Nature.